Gilead ordered to pay rival record $2.5 billion in royalties

16 December 2016
2019_biotech_test_vial_discovery_big

Gilead Sciences (Nasdaq: GILD) plans to appeal against a federal jury’s decision to hand the company a record fine in a US patent infringement case.

The biotech company was found to have infringed the patent of fellow US company Merck & Co (NYSE: MRK) in its development of the big-selling hepatitis C drugs, Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir).

These drugs account for more than half of Gilead’s revenue and the judge in the case decided that 10% of its takings from the treatments were owed to Merck, so came to a figure for the royalties of $2.54 billion, reports Bloomberg in its coverage of the case.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology